TargetBeta
TNFRSF8
TNF receptor superfamily member 8 · also KI-1, CD30, D1S166E · CD molecules
2 programs in company-led studies act on TNFRSF8, from 1 company: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Brentuximab Vedotinrule | Pfizer | – | phase 4 | 374 running | TNF | NCIt |
| PF-08046044 | Pfizer | – | phase 1 | 10 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Hodgkin Disease, 2 programs
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, Large-Cell, Anaplastic, 1 program
- Lymphoma, T-Cell, Peripheral, 1 program
- Melanoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2028Brentuximab Vedotin · Pfizer · phase 4 · NCT06831370
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.